XML 98 R21.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Segment Information | 15. Segment Information The Company’s businesses lines are organized, managed, and internally reported as five operating segments. One of these operating segments, Product Packaging, is the Company’s packaging and printing group. Product Packaging operates in the paper board folding carton, smart packaging, and document security printing markets. It markets, manufactures, and sells mailers, photo sleeves, sophisticated custom folding cartons, and complex 3-dimensional direct mail solutions. These products are designed to provide functionality and marketability while also providing counterfeit protection. A second, Biotechnology, invests in, or acquires companies in the biohealth and biomedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Biotechnology is also targeting unmet, urgent medical needs. A third operating segment, Securities and Investment Management (“Securities”) was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Further, Securities, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, stable coins and cryptocurrency via a digital asset trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, STO and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). Also in this segment is the Company’s real estate investment trust (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. The fourth segment, Direct, provides services to assist companies in the emerging growth gig business model of peer-to-peer decentralized sharing marketplaces. It specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct marketing products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific and Eastern Europe. The fifth business line, Commercial Banking, is organized for the purposes of being a financial network holding company, focused providing commercial loans and on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting, and advisory capital raising services. From this financial platform, the Company shall provide an integrated suite of financial services for businesses that shall include commercial business lines of credit, land development financing, inventory financing, third party loan servicing, and services that address the financial needs of the world Gig Economy. Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2025 and 2024 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment
Three Months Ended September 30, 2025 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 4,935,000 |  |  | $ | 7,000 |  |  | $ | - |  |  | $ | 11,000 |  |  | $ | 1,439,000 |  |  | $ | - |  |  | $ | 6,392,000 |
Cost of revenue |  |  | 4,380,000 |  |  |  | (192,000 | ) |  |  | - |  |  |  | 12,000 |  |  |  | 1,868,000 |  |  |  | - |  |  |  | 6,068,000 |
Gross profit (loss) |  |  | 555,000 |  |  |  | 199,000 |  |  |  | - |  |  |  | (1,000 | ) |  |  | (429,000 | ) |  |  | - |  |  |  | 324,000 |
Operating expense |  |  | 894,000 |  |  |  | 57,000 |  |  |  | (7,587,000 | ) |  |  | 883,000 |  |  |  | (1,754,000 | ) |  |  | 11,065,000 |  |  |  | 3,558,000 |
Operating income (loss) |  |  | (339,000 | ) |  |  | 142,000 |  |  |  | 7,587,000 |  |  |  | (884,000 | ) |  |  | 1,325,000 |  |  |  | (11,065,000 | ) |  |  | (3,234,000 | )
Other income (expense) |  |  | (35,000 | ) |  |  | 370,000 |  |  |  | (21,000 | ) |  |  | 3,000 |  |  |  | 609,000 |  |  |  | 79,000 |  |  |  | 1,005,000 |
Net income (loss) from operations before taxes |  |  | (374,000 | ) |  |  | 512,000 |  |  |  | 7,566,000 |  |  |  | (881,000 | ) |  |  | 1,934,000 |  |  |  | (10,986,000 | ) |  |  | (2,229,000 | )
Three Months Ended September 30, 2024 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 4,846,000 |  |  | $ | 45,000 |  |  | $ | - |  |  | $ | 1,000 |  |  | $ | 707,000 |  |  | $ | - |  |  | $ | 5,599,000 |
Cost of revenue |  |  | 4,350,000 |  |  |  | 252,000 |  |  |  | (2,000 | ) |  |  | 10,000 |  |  |  | 1,993,000 |  |  |  | - |  |  |  | 6,603,000 |
Gross profit (loss) |  |  | 496,000 |  |  |  | (207,000 | ) |  |  | 2,000 |  |  |  | (9,000 | ) |  |  | (1,286,000 | ) |  |  | - |  |  |  | (1,004,000 | )
Operating expense |  |  | 766,000 |  |  |  | 104,000 |  |  |  | 73,000 |  |  |  | 1,169,000 |  |  |  | 901,000 |  |  |  | 654,000 |  |  |  | 3,667,000 |
Operating income (loss) |  |  | (270,000 | ) |  |  | (311,000 | ) |  |  | (71,000 | ) |  |  | (1,178,000 | ) |  |  | (2,187,000 | ) |  |  | (654,000 | ) |  |  | (4,671,000 | )
Other income (expense) |  |  | (43,000 | ) |  |  | 251,000 |  |  |  | (52,000 | ) |  |  | (573,000 | ) |  |  | 336,000 |  |  |  | (949,000 | ) |  |  | (1,030,000 | )
Net income (loss) from operations before taxes |  |  | (313,000 | ) |  |  | (60,000 | ) |  |  | (123,000 | ) |  |  | (1,751,000 | ) |  |  | (1,851,000 | ) |  |  | (1,603,000 | ) |  |  | (5,701,000 | )
Nine Months Ended September 30, 2025 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 13,221,000 |  |  | $ | 37,000 |  |  | $ | - |  |  | $ | 32,000 |  |  | $ | 3,340,000 |  |  | $ | - |  |  | $ | 16,630,000 |
Cost of Revenue |  |  | 12,274,000 |  |  |  | 20,000 |  |  |  | (7,000 | ) |  |  | 36,000 |  |  |  | 4,430,000 |  |  |  | - |  |  |  | 16,753,000 |
Gross profit (loss) |  |  | 947,000 |  |  |  | 17,000 |  |  |  | 7,000 |  |  |  | (4,000 | ) |  |  | (1,090,000 | ) |  |  | - |  |  |  | (123,000 | )
Operating expense |  |  | 2,357,000 |  |  |  | 197,000 |  |  |  | (7,519,000 | ) |  |  | 3,124,000 |  |  |  | (855,000 | ) |  |  | 12,957,000 |  |  |  | 10,261,000 |
Operating income (loss) |  |  | (1,410,000 | ) |  |  | (180,000 | ) |  |  | 7,526,000 |  |  |  | (3,128,000 | ) |  |  | (235,000 | ) |  |  | (12,957,000 | ) |  |  | (10,384,000 | )
Other income (expense) |  |  | (110,000 | ) |  |  | (46,000 | ) |  |  | (22,000 | ) |  |  | 49,000 |  |  |  | (318,000 | ) |  |  | 677,000 |  |  |  | 230,000 |
Net income (loss) from operations |  |  | (1,520,000 | ) |  |  | (226,000 | ) |  |  | 7,504,000 |  |  |  | (3,079,000 | ) |  |  | (553,000 | ) |  |  | (12,280,000 | ) |  |  | (10,154,000 | )
Nine Months Ended September 30,2024 |  | Product Packaging |  |  | Commercial Lending |  |  | Direct Marketing |  |  | Biotechnology |  |  | Securities |  |  | Corporate |  |  | Total |
Revenue |  | $ | 11,466,000 |  |  | $ | 192,000 |  |  | $ | 3,000 |  |  | $ | 2,000 |  |  | $ | 2,018,000 |  |  | $ | - |  |  | $ | 13,681,000 |
Cost of revenue |  |  | 10,715,000 |  |  |  | 719,000 |  |  |  | (2,000 | ) |  |  | 30,000 |  |  |  | 5,804,000 |  |  |  | - |  |  |  | 17,266,000 |
Gross profit (loss) |  |  | 751,000 |  |  |  | (527,000 | ) |  |  | 5,000 |  |  |  | (28,000 | ) |  |  | (3,786,000 | ) |  |  | - |  |  |  | (3,585,000 | )
Operating expense |  |  | 2,313,000 |  |  |  | 338,000 |  |  |  | 227,000 |  |  |  | 2,637,000 |  |  |  | 3,023,000 |  |  |  | 2,164,000 |  |  |  | 10,702,000 |
Operating income (loss) |  |  | (1,562,000 | ) |  |  | (865,000 | ) |  |  | (222,000 | ) |  |  | (2,665,000 | ) |  |  | (6,809,000 | ) |  |  | (2,164,000 | ) |  |  | (14,287,000 | )
Other income (expense) |  |  | (118,000 | ) |  |  | (73,000 | ) |  |  | 134,000 |  |  |  | (699,000 | ) |  |  | 52,000 |  |  |  | (934,000 | ) |  |  | (1,638,000 | )
Net loss from operations |  |  | (1,680,000 | ) |  |  | (938,000 | ) |  |  | (88,000 | ) |  |  | (3,364,000 | ) |  |  | (6,757,000 | ) |  |  | (3,098,000 | ) |  |  | (15,925,000 | )
The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information:
Three months ended September 30, 2025 |  |  |
Packaging Printing and Fabrication |  | $ | 4,841,000 |
Commercial and Security Printing |  |  | 78,000 |
Real Property Rental Income |  |  | 16,000 |
Total Printed Products Revenue |  | $ | 4,935,000 |
Three months ended September 30, 2024 |  |  |
Packaging Printing and Fabrication |  | $ | 4,773,000 |
Commercial and Security Printing |  |  | 55,000 |
Real Property Rental Income |  |  | 18,000 |
Total Printed Products Revenue |  | $ | 4,846,000 |
Nine months ended September 30, 2025 |  |  |
Packaging Printing and Fabrication |  | $ | 12,839,000 |
Commercial and Security Printing |  |  | 334,000 |
Real Property Rental Income |  |  | 48,000 |
Total Printed Products Revenue |  | $ | 13,221,000 |
Nine months ended September 30, 2024 |  |  |
Packaging Printing and Fabrication |  | $ | 11,080,000 |
Commercial and Security Printing |  |  | 333,000 |
Real Property Rental Income |  |  | 53,000 |
Total Printed Products Revenue |  | $ | 11,466,000 |
Commercial Lending Revenue Information: |
Three months ended September 30, 2025 |  |  |
Net Investment Income |  | $ | 7,000 |
Total Commercial Lending Revenue |  | $ | 7,000 |
Three months ended September 30, 2024 |  |  |
Net Investment Income |  | $ | 45,000 |
Total Commercial Lending Revenue |  | $ | 45,000 |
Nine months ended September 30, 2025 |  |  |
Net investment income |  | $ | 37,000 |
Total Commercial Lending Revenue |  | $ | 37,000 |
Nine months ended September 30, 2024 |  |  |
Net Investment Income |  | $ | 192,000 |
Total Commercial Lending Revenue |  | $ | 192,000 |
Nine months ended September 30, 2024 |  |  |
Retail sales |  | $ | 3,000 |
Total Direct Marketing Revenue |  | $ | 3,000 |
Biotechnology Revenue Information: |  |  |
Three months ended September 30, 2025 |  |  |
Retail internet sales |  | $ | 11,000 |
Total Biotechnology Revenue |  | $ | 11,000 |
Three months ended September 30, 2024 |  |  |
Retail internet sales |  | $ | 1,000 |
Total Biotechnology Revenue |  | $ | 1,000 |
Nine months ended September 30, 2025 |  |  |
Retail internet sales |  | $ | 32,000 |
Total Biotechnology Revenue |  | $ | 32,000 |
Nine months ended September 30, 2024 |  |  |
Retail internet sales |  | $ | 2,000 |
Total Biotechnology Revenue |  | $ | 2,000 |
Securities Revenue Information: |
Three months ended September 30, 2025 |  |  |
Rental income |  | $ | 702,000 |
Commission income |  | $ | 737,000 |
Total Securities Revenue |  | $ | 1,439,000 |
Three months ended September 30, 2024 |  |  |
Rental income |  | $ | 478,000 |
Commission income |  | $ | 229,000 |
Total Securities Revenue |  | $ | 707,000 |
Nine months ended September 30, 2025 |  |  |
Rental income |  | $ | 2,099,000 |
Commission income |  | $ | 1,241,000 |
Total Securities Revenue |  | $ | 3,340,000 |
Nine months ended September 30, 2024 |  |  |
Rental income |  | $ | 1,281,000 |
Commission income |  | $ | 737,000 |
Total Securities Revenue |  | $ | 2,018,000 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration